Medical Chronicle November/December 2013 | страница 2
Cipla’s multiple therapy
CNS basket
SAVE UP
TO 50% vs.
LEADING
GENERIC1
THE MOST
COST-EFFECTIVE
QUETIAPINE
NEW
72%
Ris
Ris nia
p
0.5 erid
/ 1 one
/2
/3
VS. ORIGINATOR 1
er
tos ine
e
Quetiap /
Qu / 100 0
0
25 / 3
00
2
72%
SAVE UP TO
VS. ORIGINATORS 1
Ol
e
Ol xar
an
2.5 zap
/ 5 ine
/ 10
ec ine
pit otrig
E
/
m
La / 50 0
25 / 20
0
10
THE MOST
COST-EFFECTIVE
OLANZAPINE
Quality
Do
n
Do ece
ne pt
5 / pe
10 zil
Variety
Sustainability
n
Do
e
p
ce
t
In
I
Innovation
Affordability
S5 Reg. No. 37/2.6.5/0316, 0317, 0318
S5 Reg. No. 43/2.6.5/0800, 0801, 0802, 0803
S5 Reg. No. 38/2.5/0571, 0572, 0573, 0574
REFERENCE:
1. SEP (excl. VAT) as per DOH 14/06/2013
S5 Reg. No. 42/2.6.5/0792, 0793,0794,0795
S5 Reg. No. 42/5.3/0490, 0491
Cipla Medpro (Pty) Ltd. Reg. No. 1995/004182/07, Building 9, Parc du Cap, Mispel Street, Bellville, 7530, RSA. Tel (021) 943 4200, Fax (021) 914 4699.
E-mail: [email protected] Website: www.cipla.co.za Customer Care: 080 222 6662